Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) has announced that it will showcase detailed findings from its pivotal Phase 3 CORE and CORE2 studies on olezarsen, a treatment for severe hypertriglyceridemia (sHTG). This presentation is scheduled for a late-breaking session titled “Groundbreaking Trials in Cardiometabolic Therapeutics” at the upcoming American Heart Association (AHA) Scientific Sessions in New Orleans.
The CORE and CORE2 studies represent significant advancements in cardiometabolic therapies, particularly for individuals suffering from high triglyceride levels. These studies aim to provide deeper insights into the efficacy and safety of olezarsen, which has garnered attention for its potential to address the urgent medical need in this patient population.
As the AHA Scientific Sessions approach, the presentation of these pivotal results is highly anticipated within the medical community, emphasizing the importance of continued research and innovation in managing cardiometabolic disorders.
